Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pyxis Oncology's cash to debt ratio for the quarter that ended in Dec. 2022 was 9.48.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pyxis Oncology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2022.
The historical rank and industry rank for Pyxis Oncology's Cash-to-Debt or its related term are showing as below:
PYXS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 9.48 Med: 661.51 Max: 1665.06
Current: 9.48
During the past 4 years, Pyxis Oncology's highest Cash to Debt Ratio was 1665.06. The lowest was 9.48. And the median was 661.51.
PYXS's Cash-to-Debt is ranked better than 50.76% of 1570
companies
in the Biotechnology industry
Industry Median: 9.11
vs PYXS: 9.48
Pyxis Oncology Cash-to-Debt Historical Data
The historical data trend for Pyxis Oncology's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Pyxis Oncology Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Cash-to-Debt
1,312.67
10.36
1,665.06
9.48
Pyxis Oncology Quarterly Data
Dec19
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Cash-to-Debt
1,665.06
No Debt
14.24
12.37
9.48
Competitive Comparison
For the Biotechnology subindustry, Pyxis Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's Cash-to-Debt falls in comparison to its industry or sector. The grey bar indicates the Cash-to-Debt's extreme value range as defined by GuruFocus.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Pyxis Oncology Cash-to-Debt Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.22(11.4%) Volume: 571,453 12:55PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
PYXS has been successfully added to your 
